Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Methylprednisolone Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.75 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.75 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 6/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.78 |
| ▸ | AR | P10275 | 3/20 | 0.78 |
| ▸ | F2 | P00734 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL6 | P05231 | 1/20 | 0.53 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | GLUL | P15104 | 1/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone Phosphoric Acid SCHEMBL9390445 | 0.93 | PGR (0.79) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Phosphoric Acid SCHEMBL10802249 | 0.93 | PGR (0.79) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Phosphoric Acid SCHEMBL17131135 | 0.93 | PGR (0.79) | PGRCYP3A4ARF2NR3C1 | |
| SCHEMBL10798825 | 0.92 | PGR (0.78) | PGRCYP3A4ARF2NR3C1 | |
| SCHEMBL10800461 | 0.90 | PGR (0.74) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone SCHEMBL27599404 | 0.89 | HIF1A (0.88) | PGRCYP3A4ARF2NR3C1 | |
| SCHEMBL14019943 | 0.89 | PGR (0.81) | PGRCYP3A4ARF2NR3C1 | |
| SCHEMBL13524496 | 0.89 | PGR (0.84) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL3437554 | 0.87 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL21546231 | 0.87 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108050-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | DOMPE' FARMACEUTICI SPA (IT) | 2023-04-06 | — | — | US | claimed |
| EP-4106738-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | claimed |
| US-20220096498-A1 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | FORDOZ PHARMA CORP. (US) | 2022-03-31 | — | — | US | claimed |
| CN-113795246-A | Injectable sustained release formulation for the treatment of joint pain and inflammation | 福多兹制药公司 | 2021-12-14 | — | — | CN | claimed |
| WO-2020227353-A1 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | FORDOZ PHARMA CORP. (US) | 2020-11-12 | — | — | WO | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| US-12589102-B2 | Injectable sustained-release formulations for treatment of joint pain and inflammation | FORDOZ PHARMA CORP. (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2025264734-A1 | COLLAGEN MACROPEPTIDE PREPARATIONS AND USES THEREOF | BIOVENTUS LLC (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250381250-A1 | COLLAGEN MACROPEPTIDE PREPARATIONS AND USES THEREOF | BIOVENTUS LLC (US) | 2025-12-18 | — | — | US | disclosed |
| CN-113795246-B | Injectable sustained release formulation for the treatment of joint pain and inflammation | 福多兹制药公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-115484943-B | Combination of CXCL8 (interleukin-8) activity inhibitor and corticosteroid, pharmaceutical composition and use thereof | 导博药物公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230108050-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | DOMPE' FARMACEUTICI SPA (IT) | 2023-04-06 | — | — | US | disclosed |
| EP-4106738-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
| US-5326761-A | Suspension; sustained release | MERCK SHARP & DOHME-CHIBRET (FR) | 1994-07-05 | — | — | US | disclosed |
| EP-0437368-B1 | Fluid ophthalmic composition based on lipid microparticles containing at least one active principle | MERCK SHARP & DOHME (FR) | 1994-03-02 | — | — | EP | disclosed |
| EP-0437368-A1 | Fluid ophthalmic composition based on lipid microparticles containing at least one active principle | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108050-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CXCL8, CCR8, MMP8 | NR3C1 91/4885PDE4D 205/4885ADORA3 1251/4885 |
| US-12589102-B2 | Injectable sustained-release formulations for treatment of joint pain and inflammation | IL1B, TNF, MIF | NR3C1 25/4885PDE4D 4643/4885ADORA3 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.